NRG-BR008

Open to Accrual

Return to Protocol Table

NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)

Principal Investigator

Lior Braunstein, MD

Co-Principal Investigator(s)

Melissa Mitchell, MD

Status

Open to Accrual

Date Opened To Accrual

March 13 2023

Disease Site

Breast [BR]

Breast

Phase

III

Developmental Therapeutics

Primary Objective

To compare the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the current standard of care.

Patient Population

Patients with low-risk HER2-positive breast cancer

Target Accrual

1300

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

NRG-BR008 Webinar Recording login req'd to view (October 2024)
NRG-BR008, the HERO Study Interview with Lior Braunstein, MD & Melissa Mitchell, MD (Feb 2024)
NRG-BR008, the HERO Study Overview by Lior Braunstein, MD (Jan 2023)
NRG-BR008 Webinar Recording (August 2023)

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.